[A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
This case is a 71-year-old female. As hormonotherapy, 400 mg/day of MPA alone was orally administered in a lung metastatic case of cancer of the uterine body in the IV stage. Although progressing for 2 years and 1 month after the initial administration, lung metastatic foci disappeared, and recurrence was not noted, and serious side effect by using MPA was also not noted. Progesterone therapy such this case is considered as one of therapeutic methods which can be expected remarkably effective rate in the lu metastatic foci of cancer of the uterine body.
Takeda
M
M
First Dept. of Internal Medicine, School of Medicine, Shinshu University.
Kubo
K
K
Fukushima
M
M
Hirayama
J
J
Sekiguchi
M
M
D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D012074:Remission Induction; D014594:Uterine Neoplasms / Q000473:pathology*
D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone